B Capital, a NYC-based global multi-stage investment firm, closed the inaugural B Capital Healthcare Fund I.
In conjunction with B Capital Growth Fund III, the new fund allocates over $500m to opportunities across the healthcare sector, from digital health to biotech.
The fund will be led by Robert Mittendorff, MD, General Partner and Head of Healthcare at B Capital. Dr. Mittendorff joined B Capital in April 2021 to lead Healthcare Fund I and B Capital’s broader healthcare initiatives globally. The B Capital Healthcare team is focused on deploying capital to category-defining companies that are building breakthrough products and solutions shaping the future of healthcare.
The current B Capital global healthcare portfolio includes over 20 companies in the US, Asia and Europe, spanning early venture to late growth venture, across healthtech, digital health, biotech and medtech. Notably, the team co-led the latest round of investment in Hotspot Therapeutics, an AI-enabled drug discovery company, and led the latest round in Triumvira, a novel cell therapy platform in clinical development. The team also led the latest financing in CapitalRX, a tech platform for pharmacy benefits management. In medtech, the team led the last round in Carlsmed, an AI-enabled personalized spinal implant company.
In January 2023, B Capital announced the close of Growth Fund III with aggregate capital commitments of approximately $2.1 billion. With the close of B Capital’s Healthcare Fund I and the third venture growth fund, B Capital’s total assets under management are approximately $6.3 billion.
Founded in 2015, B Capital is a multi-stage global investment firm that focuses on seed to late-stage venture growth investments, primarily in the enterprise, financial technology and healthcare sectors. The firm leverages an integrated team across nine locations in the US and Asia, as well as a strategic partnership with BCG, to provide the value-added support entrepreneurs need to scale fast and efficiently, expand into new markets and build exceptional companies.
FinSMEs
01/03/2023